{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:29:52Z","timestamp":1781105392319,"version":"3.54.1"},"reference-count":22,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1297\/cpe.2023-0061","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T17:12:04Z","timestamp":1707412324000},"page":"76-81","source":"Crossref","is-referenced-by-count":2,"title":["Fatality owing to pulmonary hemorrhage following pamidronate disodium          administration in a neonate with osteogenesis imperfecta type 2: A case          report"],"prefix":"10.1297","volume":"33","author":[{"given":"Rintaro","family":"Nagoshi","sequence":"first","affiliation":[{"name":"Center for Postgraduate Education and Training, National Center for Child              Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Amari","sequence":"additional","affiliation":[{"name":"Center for Postgraduate Education and Training, National Center for Child              Health and Development, Tokyo, Japan"},{"name":"Division of Neonatology, Center for Maternal-Fetal, Neonatal and              Reproductive Medicine, National Center for Child Health and Development, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Abiko","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yamagata University Hospital, Yamagata,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sano Wada","sequence":"additional","affiliation":[{"name":"Center for Postgraduate Education and Training, National Center for Child              Health and Development, Tokyo, Japan"},{"name":"Division of Neonatology, Center for Maternal-Fetal, Neonatal and              Reproductive Medicine, National Center for Child Health and Development, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Center for Postgraduate Education and Training, National Center for Child              Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Horikawa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, National Center for Child Health              and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Center for Maternal-Fetal, Neonatal and              Reproductive Medicine, National Center for Child Health and Development, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Van                Dijk, FS,                Sillence,              DO.            Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity            assessment. Am J Med Genet A          2014;164A: 1470\u201381.","DOI":"10.1002\/ajmg.a.36545"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Marom,              R,              Rabenhorst,              BM, Morello,                R.            Osteogenesis imperfecta: an update on clinical features and            therapies. Eur J Endocrinol          2020;183: R95\u2013106.","DOI":"10.1530\/EJE-20-0299"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dwan,              K, Phillipi,                CA,              Steiner, RD,                Basel,            D. Bisphosphonate            therapy for osteogenesis imperfecta. Cochrane Database Syst            Rev          2016;10: CD005088.","DOI":"10.1002\/14651858.CD005088.pub4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Glorieux,                FH, Bishop,                NJ,              Plotkin, H,                Chabot, G,                Lanoue, G,                Travers,            R. Cyclic            administration of pamidronate in children with severe osteogenesis            imperfecta. N Engl J Med          1998;339: 947\u201352.","DOI":"10.1056\/NEJM199810013391402"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kara,              C, \u00c7etinkaya,                S, G\u00fcnd\u00fcz,                S, Can                Y\u0131lmaz, G,                Aycan, Z,                Ayd\u0131n,            M. Efficacy and            safety of pamidronate in children with vitamin D intoxication.            Pediatr Int          2016;58: 562\u20138.","DOI":"10.1111\/ped.12875"},{"key":"6","unstructured":"6. ClinVar [Internet]. Bethesda (MD): U.S. National          Center for Biotechnology Information; NM_000089.4(COL1A2):c.2891G>A (p.Gly964Asp);          [cited 2023 Nov 26]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/VCV000426606.4 Variation ID:          000426606."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Richards,                S, Aziz,                N, Bale,                S, Bick,                D, Das,                S,                Gastier-Foster,              J, et al.            ACMG Laboratory Quality Assurance Committee.            Standards and guidelines for the interpretation of sequence variants: a            joint consensus recommendation of the American College of Medical Genetics and Genomics            and the Association for Molecular Pathology. Genet Med          2015;17: 405\u201324.","DOI":"10.1038\/gim.2015.30"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Li,                Q, Wang,                K. InterVar:            Clinical interpretation of genetic variants by the 2015 ACMG-AMP            guidelines. Am J Hum Genet          2017;100: 267\u201380.","DOI":"10.1016\/j.ajhg.2017.01.004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sayre,              MR, Roberge,                RJ, Evans,                TC.            Nontraumatic subdural hematoma in a patient with osteogenesis imperfecta            and renal failure. Am J Emerg Med          1987;5: 298\u2013301.","DOI":"10.1016\/0735-6757(87)90355-X"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Evensen,                SA, Myhre,                L,                Stormorken,              H. Haemostatic            studies in osteogenesis imperfecta. Scand J Haematol          1984;33: 177\u20139.","DOI":"10.1111\/j.1600-0609.1984.tb02393.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gooijer,              K, Rondeel,                JMM, van                Dijk, FS,                Harsevoort,              AGJ, Janus,                GJM,                Franken,              AAM. Bleeding            and bruising in Osteogenesis Imperfecta: International Society on Thrombosis and            Haemostasis bleeding assessment tool and haemostasis laboratory assessment in 22            individuals. Br J Haematol          2019;187: 509\u201317.","DOI":"10.1111\/bjh.16097"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Al-Senaidi,                KS, Ullah,                I, Javad,                H,                Al-Khabori,              M,              Al-Yaarubi,            S.            Echocardiographic Evidence of Early Diastolic Dysfunction in Asymptomatic            Children with Osteogenesis Imperfecta. Sultan Qaboos Univ Med            J          2015;15: e456\u201362.","DOI":"10.18295\/squmj.2015.15.04.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tanvetyanon,                T, Stiff,                PJ.            Management of the adverse effects associated with intravenous            bisphosphonates. Ann Oncol          2006;17: 897\u2013907.","DOI":"10.1093\/annonc\/mdj105"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Munns,              CF, Rauch,                F, Mier,                RJ,                Glorieux,              FH. Respiratory            distress with pamidronate treatment in infants with severe osteogenesis            imperfecta. Bone          2004;35: 231\u20134.","DOI":"10.1016\/j.bone.2004.03.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Alapati,              D, Shaffer,                TH. Skeletal            dysplasia: Respiratory management during infancy. Respir            Med          2017;131: 18\u201326.","DOI":"10.1016\/j.rmed.2017.07.063"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bowden,              SA, Mahan,                JD.            Zoledronic acid in pediatric metabolic bone disorders.            Transl Pediatr          2017;6: 256\u201368.","DOI":"10.21037\/tp.2017.09.10"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chien,              YH, Chu,                SY, Hsu,                CC, Hwu,                WL.            Pamidronate treatment of severe osteogenesis imperfecta in a newborn            infant. J Inherit Metab Dis          2002;25: 593\u20135.","DOI":"10.1023\/A:1022099425316"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Papapetrou,                PD.            Bisphosphonate-associated adverse events.            Hormones (Athens)          2009;8: 96\u2013110.","DOI":"10.14310\/horm.2002.1226"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Rauch,              F, Plotkin,                H, Travers,                R, Zeitlin,                L,              Glorieux,            FH. Osteogenesis            imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral            metabolism. J Clin Endocrinol Metab          2003;88: 986\u201392.","DOI":"10.1210\/jc.2002-021371"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zeitlin,              L, Rauch,                F, Plotkin,                H,              Glorieux,            FH. Height and            weight development during four years of therapy with cyclical intravenous pamidronate in            children and adolescents with osteogenesis imperfecta types I, III, and            IV. Pediatrics          2003;111: 1030\u20136.","DOI":"10.1542\/peds.111.5.1030"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fored,              CM, Ejerblad,                E,              Lindblad, P,                Fryzek, JP,                Dickman,            PW, Signorello,                LB, et al.            Acetaminophen, aspirin, and chronic renal failure.            N Engl J Med          2001;345: 1801\u20138.","DOI":"10.1056\/NEJMoa010323"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ogilvie,                JD, Rieder,                MJ, Lim,                R.            Acetaminophen overdose in children. CMAJ          2012;184: 1492\u20136.","DOI":"10.1503\/cmaj.111338"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/33\/2\/33_2023-0061\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T01:05:23Z","timestamp":1711760723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/33\/2\/33_2023-0061\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.2023-0061","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"2023-0061"}}